Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway

Carcinogenesis

Volumn 35, Issue 4, 2014, Pages 776-783

  Nosho, Katsuhiko ^a   Igarashi, Hisayoshi ^a   Nojima, Masanori ^b   Ito, Miki ^a   Maruyama, Reo ^a   Yoshii, Shinji ^c,d   Naito, Takafumi ^a   Sukawa, Yasutaka ^a   Mikami, Masashi ^a   Sumioka, Wakana ^a   Yamamoto, Eiichiro ^a   Kurokawa, Sei ^a   Adachi, Yasushi ^a   Takahashi, Hiroaki ^a,c   Okuda, Hiroyuki ^a,c   Kusumi, Takaya ^c   Hosokawa, Masao ^c   Fujita, Masahiro ^c   Hasegawa, Tadashi ^a   Okita, Kenji ^a   Hirata, Koichi ^a   Suzuki, Hiromu ^a   Yamamoto, Hiroyuki ^e   Shinomura, Yasuhisa ^a   more..

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KEIYUKAI SAPPORO HOSPITAL   (Japan)

^d Nippon Telegraph and Telegraph and Telephone East Corporation   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROURACIL; MICRORNA 31; PROTEIN INHIBITOR;

AGED; ANALYSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; COLON POLYP; COLORECTAL CANCER; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM ADENOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WILD TYPE;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84898643458     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt374     Document Type: Article

References (50)

1. Network, T.C.G.A. (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330-337.
2. De Roock, W. et al. (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol., 12, 594-603.
3. Di Nicolantonio, F. et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol., 26, 5705-5712.
4. Donehower, L.A. et al. (2013) MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J. Pathol., 229, 99-110.
5. Lochhead, P. et al. (2013) Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl. Cancer Inst., 105, 1151-1156.
6. Nishikawa, E. et al. (2011) miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res., 71, 6165-6173.
7. Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
8. Zhang, T. et al. (2011) The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin. Sci. (Lond)., 121, 437-447.
9. Valastyan, S. et al. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137, 1032-1046.
10. Meng, F. et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-658.
11. Creighton, C.J. et al. (2010) Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res., 70, 1906-1915.
12. Zhang, Y. et al. (2010) Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med. Oncol., 27, 685-689.
13. Schaefer, A. et al. (2010) Diagnostic and prognostic implications of micro-RNA profiling in prostate carcinoma. Int. J. Cancer, 126, 1166-1176.
14. Ueda, T. et al. (2010) Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol., 11, 136-146.
15. Leidner, R.S. et al. (2012) The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes. Chromosomes Cancer, 51, 473-479.
16. Bartley, A.N. et al. (2011) Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin. Cancer Res., 17, 7283-7293.
17. Balaguer, F. et al. (2011) Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res., 17, 6239-6249.
18. Schetter, A.J. et al. (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425-436.
19. Shibuya, H. et al. (2010) Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology, 79, 313-320.
20. Sarver, A.L. et al. (2009) Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer, 9, 401.
21. Schee, K. et al. (2012) Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer, 12, 505.
22. Cekaite, L. et al. (2012) MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia, 14, 868-879.
23. Chang, K.H. et al. (2011) MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int. J. Colorectal Dis., 26, 1415-1422.
24. Wang, C.J. et al. (2009) Clinicopathological significance of micro-RNA-31, -143 and -145 expression in colorectal cancer. Dis. Markers, 26, 27-34.
25. Chen, X. et al. (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene, 28, 1385-1392.
26. Slaby, O. et al. (2007) Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology, 72, 397-402.
27. Bandrés, E. et al. (2006) Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer, 5, 29.
28. Earle, J.S. et al. (2010) Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J. Mol. Diagn., 12, 433-440.
29. Pagliuca, A. et al. (2013) Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene, 32, 4806-4813.
30. Arcaroli, J.J. et al. (2012) Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clin. Cancer Res., 18, 2704-2714.
31. Xiong, B. et al. (2013) MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int. J. Oncol., 42, 219-228.
32. Bakirtzi, K. et al. (2011) Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology, 141, 1749-61.e1.
33. Mosakhani, N. et al. (2012) MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes. Chromosomes Cancer, 51, 1-9.
34. Oberg, A.L. et al. (2011) miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One, 6, e20465.
35. Sun, D. et al. (2013) MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J. Biol. Chem., 288, 9508-9518.
36. Hur, K. et al. (2013) MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut, 62, 1315-1326.
37. Takahashi, M. et al. (2012) Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis, 33, 2441-2449.
38. Wu, J. et al. (2012) MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis, 33, 519-528.
39. Yu, Y. et al. (2012) MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis, 33, 68-76.
40. Bettington, M. et al. (2013) The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology, 62, 367-386.
41. Leggett, B. et al. (2010) Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology, 138, 2088-2100.
42. Rosty, C. et al. (2012) Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. Am. J. Surg. Pathol., 36, 876-882.
43. McShane, L.M. et al.; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst., 97, 1180-1184.
44. Bosman, F.T. et al. (2010) WHO Classification of Tumours of the Digestive System. International Agency for Research on Cancer, Lyon, France.
45. Liao, X. et al. (2012) Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival. N. Engl. J. Med., 367, 1596-1606.
46. Nosho, K. et al. (2009) A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology, 137, 1609-20.e1.
47. Iwagami, S. et al. (2013) LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Ann. Surg., 257, 449-455.
48. Cottonham, C.L. et al. (2010) miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J. Biol. Chem., 285, 35293-35302.
49. Torlakovic, E.E. et al. (2008) Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am. J. Surg. Pathol., 32, 21-29.
50. Schmitz, K.J. et al (2009) Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon. Virchows Arch., 455, 49-54.